

SARC SEMIANNUAL MEETING

FRIDAY, MAY 29, 2026 ♦ 7:30 AM-12 NOON CENTRAL

Northwestern Memorial Hospital, Feinberg Conference Center 3rd Floor 251 E. Huron Street, Chicago, IL, USA

7:30-8:55 am	Breakfast & Networking	Feinberg Krumlovsky Atrium
9:00-9:10 am	Welcome	Feinberg ABCD Conference Room
	<i>Opening Remarks</i>	Steven Young (SARC President & CEO) Jonathan Fletcher MD (SARC CSO; BWH)
9:10-10:20 am	Session 1: Precision Delivery in Sarcoma: Targets, Modalities, Clinical Contexts	
Introduction	<i>Session Chair</i>	Breelyn Wilky MD (CU Anschutz)
<ul style="list-style-type: none"> ○ ADCs for Osteosarcoma ○ Integrating radiopharmaceuticals in the combined modality treatment of patients with sarcoma ○ Bispecific Antibodies for Alpha Therapy 		Richard Gorlick MD (MDACC) Zachary Morris MD PhD (U. Wisconsin) Nai-Kong V Cheung MD PhD (MSKCC)
	<i>Discussion: Panel & Audience</i>	
10:20-11:40 am	Session 2: SARC Studies & Programs	Presenters
	<i>Session Chair</i>	Scott Okuno MD (SARC CMO; Mayo Clinic)
SARC Operations:		
<ul style="list-style-type: none"> ○ Clinical Trials Development Committee <ul style="list-style-type: none"> ▪ Internal and external trials development ▪ Mentoring junior staff for clinical trials 		<i>Chair: Gregory Cote MD PhD</i> (MGH) & <i>Vice Chair: Elizabeth Davis MD</i> (VUMC)
SARC Programs & Initiatives:		
<ul style="list-style-type: none"> ○ Strategic Collaborations Outside the USA ○ SARC_{TALK} The Patient Experience 		Scott Okuno MD Daphne Edgren (Northwestern U., Harvard)
SARC Clinical Trials Updates:		Scott Okuno MD / Principal Investigators (as avail.)
<ul style="list-style-type: none"> ○ <u>Open/Actively Accruing</u> <ul style="list-style-type: none"> ▪ SARC045 Ph II Tebentafusp Advanced CCS ▪ SARC046 Ph II Nab-Sirolimus in EHE ○ <u>Open/Completed Accrual</u> <ul style="list-style-type: none"> ▪ SARC044 Ph II Bezuclastinib w/Sunitinib in GIST ▪ SARC041 Ph III RCT Abemaciclib v. PLCB DDLPS ○ <u>Closed/Pending Publication</u> <ul style="list-style-type: none"> ▪ SARC037 Ph II Trabectedin w/Irinotecan & 18F-FLT Imaging in ES ▪ SARC038 Ph II Regorafenib & Nivolumab in OS ○ <u>Pending Launch</u> <ul style="list-style-type: none"> ▪ SARC048 Ph III Neoadjuvant Doxorubicin & Ifosfamide STS ▪ SARC049 Ph II Zanzalintinib Advanced MPNST 		Sandra D'Angelo MD (MSKCC) & Andrea Napolitano MD PhD (RMH) Michael Wagner MD (DFCI) Candace Haddox MD (DFCI) Mark Dickson MD (MSKCC) Patrick Grohar MD PhD (U-M) Fariba Navid MD (CHLA) & Lara Davis MD (Fred Hutch) David Liebner MD (OSU) Vanessa Eulo MD (UAB) & Angela Hirbe MD PhD (WashU)
11:40-11:55 am	Session 3: Keynote	
	<i>Author, Speaker, Cancer Survivor, Veteran</i>	Brandi Benson
11:55 am-12:00 pm	Closing Remarks/Adjourn	SARC Leadership